Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00867048 · ClinicalTrials.gov registry record · Phase 4
Strategic Timing of Antiretroviral Treatment
A Phase 4 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 4
- Development phase
- 4,688
- Enrollment target
NCT00867048: Completed Phase 4 study, sponsored by University of Minnesota.
NCT00867048 is a Phase 4 study that has completed, run by University of Minnesota. The registered enrollment target is 4,688 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (805% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00867048, a Phase 4 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 4,688 participants
- Enrollment target
Study Summary
Objectives: * To find out if the chance of developing a serious illness or of getting AIDS is less if patients start taking HIV medicines at a time when their cluster-of-differentiation-4 (CD4)+ cell count is still fairly high, instead of waiting until the CD4+ count is at the level where there is good evidence for starting medicines. * To learn more about how a strategy of starting HIV medicines early might affect other aspects of care, such as the chances of developing other illnesses or resistance to HIV medicines, the frequency of doctor visits, the cost of medical care, and general health and satisfaction.
Interventions
- DRUG All licensed antiretroviral medications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,688 participants |
| Start Date | 2009-04-15 |
| Est. Completion | 2022-07-27 |
| Phase | Phase 4 |
What the finished NCT00867048 record still lists
NCT00867048 is an interventional study that assigns participants to a tested intervention. Its 4,688 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (805% higher).
The record links to 0 conditions, and to 1 intervention - of which All licensed antiretroviral medications is the first listed.
NCT00867048 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00867048 about?
NCT00867048 is a clinical study titled "Strategic Timing of Antiretroviral Treatment". Objectives: * To find out if the chance of developing a serious illness or of getting AIDS is less if patients start taking HIV medicines at a time when their cluster-of-differentiation-4 (CD4)+ cell count is still fairly high, instead of waiting until the CD4+ count is at the level where there is ...
What is the current status of trial NCT00867048?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 4,688 participants. The study started on 2009-04-15. Estimated completion is 2022-07-27.
What interventions are being tested in trial NCT00867048?
The interventions under investigation include: All licensed antiretroviral medications (DRUG).
Who is sponsoring clinical trial NCT00867048?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00867048's enrollment target sits among peer trials
4,688 17th of 2000 higher than 1,984 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04371900 · 4,700 participants · NA
Michigan Contraceptive Access, Research, and Evaluation Study Children: Phase 1
- NCT05486572 · 4,700 participants · NA
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- NCT06888388 · 4,700 participants
Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer
- NCT06535139 · 4,630 participants · NA
ReMARK: Addressing Disparities in Rural HPV-related Cancer Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI